High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
Introduction: Hormone receptor (HR)-positive metastatic breast cancer (MBC) is usually treated with hormone therapy. In postmenopausal females, aromatase inhibitors (AIs) are usually used as first-line therapy, and fulvestrant is used subsequently. The optimal treatment beyond fulvestrant has not be...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Karger Publishers
2014-06-01
|
| Серія: | Case Reports in Oncology |
| Предмети: | |
| Онлайн доступ: | http://www.karger.com/Article/FullText/363649 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|